Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification

NCT07038967 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-06-29
Last updated
2025-07-01

Condition(s) studied

Non-CenterDiabetic Macular EdemaPhacoemulsification

Investigational drug(s) / intervention(s)

Coloured photographyFluorescein angiographyOptical coherence tomography

Coloured photography: Coloured photography will be performed preoperatively and at 3 and 6 months postoperatively.

Fluorescein angiography: Fluorescein angiography will be performed preoperatively and at 3 and 6 months postoperatively. The following features will be recorded on each angiography:

Optical coherence tomography: Optical coherence tomography (OCT) scanning will be performed using the optical coherence tomography scanner OCT (OPTOVUE OCT). OCT will be performed preoperatively and at 3 and 6 months postoperatively.

Study summary

This study aims to evaluate the progression of non-center-involving diabetic macular edema in the early postoperative period following phacoemulsification.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years. * Both sexes. * Patients with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME). Exclusion Criteria: * Traumatic cataract. * Severe Non-Proliferative/ Proliferative Diabetic Retinopathy. * Marked Asymmetry of retinopathy between both eyes. * Mature senile cataract or severe lens opacity. * Potentiality to have Phacotrabeculectomy surgery. * Complications during or after the surgery.

Primary outcome measure(s)

  • Best Corrected Visual Acuity — 6 months post-procedure
    Best Corrected Visual Acuity (BCVA) will be recorded.

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07038967 on ClinicalTrials.gov ↗ ← All trials in Egypt